Treatments

The following database contains products that have been granted orphan status, or have been market approval in the EU or the USA.

You can filter the content by clicking on the titles: Product, Indication, Sponsor and Date. Clicking once, will filter the column alphabetically from A – Z and a second click on the same title will filter from Z – A.

Become a Partner.

Country Product Indication Sponsor Date
Desmoglein 3 synthetic peptide (PI-0824) Pemphigus vulgaris Peptimmune, Inc.;64 Sidney Street;Cambridge, Massachusetts, 02139 October 26, 2004
L, 1′-[1,4-phenylenebis (methylene)]-bis-1,4,8,11- tetraazacyclotetradecane Treatment to mobilize progenitor cells prior to stem cell transplantation Genzyme Europe B.V. October 20, 2004
Bevacizumab Pancreatic Cancer Genentech, Inc.;1 DNA Way, MS #242;South San Francisco, California, 94080 October 20, 2004
Temozolomide Glioma Merck & Company;2000 Galloping Hill Road;Kenilworth, New Jersey, 07033 October 18, 2004
Sorafenib Renal cancer Bayer Pharmaceutical Corporation;400 Morgan Lane;West Haven, Connecticut, 06516 October 8, 2004
Plitidepsin Multiple myeloma PharmaMar USA, Inc.;205 East 42nd St., Suite 15003;New York, New York, 10017 September 30, 2004
N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide Neuroblastoma AbbVie, Inc.;1 N. Waukegan Road;North Chicago, Illinois, 60064 September 30, 2004
Nitric oxide To reduce the risk of chronic lung disease in premature neonates Mallinckrodt Hospital Products;1425 U.S. 206;Bedminster Township, New Jersey, 07921 September 27, 2004
Thalidomide Myelodysplastic syndrome Celgene Corporation;86 Morris Avenue;Summit, New Jersey, 07901 September 27, 2004
Human anti-CD30 monoclonal antibody Hodgkin’s disease Bristol-Myers Squibb, Inc.;519 Route 173 West;Bloomsbury, New Jersey, 08804 September 27, 2004
Immune Globulin Subcutaneous (Human) Patients with primary immune deficiency (PID) that are intolerant to immune globulin intravenous (IGIV) due to severe adverse events or poor venous access CSL Behring;1020 First Avenue, P.O. Box 61501;King of Prussia, Pennsylvania, 19406 September 22, 2004
Coagulation factor VIIa (recombinant) Congenital Factor VII deficiency Novo Nordisk, Inc.;100 College Road West;Princeton, New Jersey, 08540 September 10, 2004
Coagulation factor VIIa (recombinant) Congenital Factor VII deficiency Novo Nordisk, Inc.;100 College Road West;Princeton, New Jersey, 08540 September 10, 2004
L-tyrosine-L-serine-L-leucine Hepatocellular Carcinoma CMS Peptides Patent Holding Company Limited;Unit 2106, 21st Floor, Island Place Tower, 510 King's Rd;North Point September 10, 2004
Tanespimycin Multiple myeloma Bristol-Myers Squibb;Research and Development, 5 Research Parkway;Wallingford, Connecticut, 06492 September 9, 2004
Buffered Ursodeoxycholic Acid Alagille syndrome Digestive Care, Inc.;1120 Win Drive;Bethlehem, Pennsylvania, 18017 September 3, 2004
Nine amino acid polypeptide derived from proteinase 3 Myelodysplastic syndromes The Vaccine Company;P. O. Box 93921;Carmel, California, 93921 September 3, 2004
17-allylamino-17-demethoxygeldanamycin (17-AGG) Chronic myeloid leukemia Bristol-Myers Squibb Company;Research & Development, 5 Research Parkway;Wallingford, Connecticut, 06492 September 3, 2004
Autologous incubated macrophage Therapy to improve the motor and sensory neurological outcome in acute cases of spinal cord injury Proneuron Biotechnologies, Inc.;2029 Century Park East, Sixth Floor;Los Angeles, California, 90067 September 3, 2004
Nine amino acid polypeptide derived from proteinase 3 Chronic myeloid leukemia The Vaccine Company;P. O. Box 93921;Carmel, California, 93921 September 3, 2004
Nine amino acid polypeptide derived from proteinase 3 Acute myeloid leukemia The Vaccine Company;P. O. Box 93921;Carmel, California, 93921 September 3, 2004
A10 & AS2-1 Antineoplaston Glioma Burzynski Research Institute, Inc.;9432 Old Katy Road;Houston, Texas, 77055 September 3, 2004
Ataluren Cystic fibrosis PTC Therapeutics, Inc.;100 Corporate Court;South Plainfield, New Jersey, 07080 September 1, 2004
Allogeneic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor Retinitis pigmentosa Neurotech USA, Inc.;6 Blackstone Valley Place;Lincoln, Rhode Island, 02865 September 1, 2004
Alpha1-Proteinase Inhibitor (Human) Cystic fibrosis Kamada Ltd.;7 Sapir Street;Ness Ziona September 1, 2004